Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...
In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients
In a study published in Blood Advances, investigators reviewed data from a large cohort of patients who had undergone a hematopoietic cell transplantation (HCT)...
Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma
Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...
Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs
Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...
Lower Risk of GVHD With Parous Female Sibling Donors Than With Male Unrelated Donors
Donor’s sex and number of previous pregnancies are well established risk factors for graft-versus-host disease (GVHD) in hematopoietic cell transplantation (HCT), with male sibling...
Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions
In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...
DOACs Versus Warfarin in Patients With Cancer and Atrial Fibrillation
Newer direct oral anticoagulants (DOACs) offer an effective alternative to warfarin that does not require monitoring, but these agents are often not recommended in...
Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia
In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...
Understanding Bone Disease and Fractures in Patients With MGUS
Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...
Previous Malignancy May Increase Risk of Subsequent Malignancy in Patients With Myeloma
A number of new treatments for patients with multiple myeloma (MM) have become available in recent years, enabling patients to live longer. Unfortunately, these...
Current Issue
September 2018, Volume 4, Issue 11
View issue flipbook
September 2018
Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...
